RET and hereditary clear cell renal cell carcinoma: Several inhibitors with anti-RET activity have been approved by FDA, such as sunitinib for the treatment of renal cell carcinoma and neoplasms, sorafenib, lenvatinib and vandetanib for the treatment of differentiated thyroid cancer subtypes5,7.